Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a CAGR of 49.10% by 2034, estimates DelveInsight

DelveInsight's "Intratumoral Cancer Therapies Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Intratumoral Cancer Therapies epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Intratumoral Cancer Therapies therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Intratumoral Cancer Therapies Market Report
• In December 2025- Philogen S.p.A announced a study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of Daromun neoadjuvant intratumoral treatment followed by surgery and adjuvant therapy versus surgery and adjuvant therapy in clinical stage III B/C/D melanoma patients. 186 patients will be randomized in a 1:1 ratio to receive Daromun treatment followed by surgery and adjuvant therapy (Arm 1) or surgery and adjuvant therapy (Arm 2).
• The United States accounts for approximately 80% Intratumoral Cancer Therapies Market Share.
• Among EU4 and the UK, Germany accounted for the highest Intratumoral Cancer Therapies Market Share, followed by France whereas Spain accounted for the lowest market.
• Among the selected indications for intratumoral therapies, non-melanoma accounted for the highest number of cases across the 7MM and is anticipated to increase at ~ 2.0% in the coming decade. Further, in the US, breast cancer constitutes approximately 30% of cancer cases, with the Intratumoral Cancer Therapies Incidence rate steadily increasing.
• Currently, only IMLYGIC is approved by the US FDA for melanoma treatment and garnered more than 90% of the total intratumoral therapies market.
• The leading Intratumoral Cancer Therapies Companies such as Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix, and others.
• Promising Intratumoral Cancer Therapies such as RiMO-301, Hiltonol, Pembrolizumab, SD-101, Leuprolide acetate, Daromun, BB-401, INT230-6 and others.

Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapies Epidemiology Segmentation in the 7MM
• Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)
• Target patient Pool of Intratumoral therapies by Cancer Types
• Treated cases by Cancer Types

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral cancer therapies Marketed Drugs
• IMLYGIC (talimogene laherparepvec): Amgen
IMLYGIC (T-VEC) by Amgen, the first oncolytic virus, was approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after the initial surgery in 2015. After few months, in December 2015, the European Commission (EC) also approved it for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC, and IVM1a), with no bone, brain, lung or other visceral diseases. It is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF).

• DELYTACT (G47Δ): Daiichi Sankyo
DELYTACT is a triple-mutated, replication-conditional herpes simplex virus type 1 (HSV-1) that has been developed to replicate only in cancer cells. In 2021, it received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) to commercialize only at hospitals (served as trial sites) for the treatment of patients with malignant glioma. for a duration of 7 years. Approval was based on data from a single-arm phase II trial which showed that DELYTACT improved chances of survival at one year in patients with residual or recurrent glioblastoma previously treated with radiotherapy and temozolomide chemotherapy who residual or recurrent disease. It is the first oncolytic virus therapy to be launched anywhere in the world for brain cancer, and only the third oncolytic virus therapy to be made available to patients worldwide.

Intratumoral Cancer Therapies Emerging Drugs
• HENSIFY: Nanobiotix
HENSIFY, a first-in-class product, introduces a new, physical Intratumoral Cancer Therapies mechanism of action. It was designed by Nanobiotix to physically destroy tumors and activate the immune system for local control and systemic disease treatment when combined with radiation therapy. In addition to HENSIFY, NBTXR3 is currently under evaluation in various other indications such as lung, head, neck, liver, and prostate cancer. It is an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into a tumor before a patient's first standard radiotherapy treatment. When exposed to ionizing radiation, HENSIFY amplifies the localized, intratumor killing effect of that radiation. X-ray dose delivered to the tumor is magnified, while the dose passing through healthy tissues remains unchanged. In February 2020, Nanobiotix announced that the US FDA had granted FTD for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for treating patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy. Currently, it is in Phase III of Intratumoral Cancer Therapies Clinical Trials development for the treatment of locally advanced head and neck squamous cell carcinoma.

• STP705 (cotsiranib): Sirnaomics
Sirnaomics' leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-β1 and COX-2 gene expression directly. The drug is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA, respectively, and formulated in nanoparticles with a proprietary histidine-lysine co-polymer (HKP) peptide. There are currently three product pipeline programs prioritized by STP705: a late-stage clinical development for Squamous Cell Carcinoma in situ (isSCC), completion of Phase II for Basal Cell Carcinoma (BCC), and Phase I for the fat remodeling. For other indications, STP705 has received an Orphan Drug Designation for the treatment of cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC).

Get expert insights and forecasts-download now! @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intratumoral Cancer Therapies Market Outlook
The Intratumoral cancer therapies market outlook is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness regarding these therapies, and the increasing number of intratumoral cancer therapies that are under investigation. To date, approved intratumoral cancer therapies include IMLYGIC (talimogene laherparepvec), and DELYTACT (G47Δ)(only approved in Japan). Currently, IMLYGIC is dominating the intratumoral cancer therapies market, however vidutolimod, and RP1 is likely to have a substantial impact on the intratumoral market landscape in the coming decade.

Intratumoral Cancer Therapies Companies
Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix, and others.

Scope of the Intratumoral Cancer Therapies Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Intratumoral Cancer Therapies Companies- Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix, and others.
• Intratumoral Cancer Therapies Pipeline Therapies- RiMO-301, Hiltonol, Pembrolizumab, SD-101, Leuprolide acetate, Daromun, BB-401, INT230-6 and others.
• Intratumoral Cancer Therapies Therapeutic Assessment: Intratumoral Cancer Therapies Current Marketed and Intratumoral Cancer Therapies Emerging Therapies
• Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market drivers and Intratumoral Cancer Therapies market barriers
• Intratumoral Cancer Therapies Unmet Needs, KOL's views, Analyst's views, Intratumoral Cancer Therapies Market Access and Reimbursement

From market size to emerging drugs-find it all in our latest report. Read now! @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Intratumoral Cancer Therapies Market Overview at a Glance
4. Intratumoral Cancer Therapies Methodology
5. Intratumoral Cancer Therapies Executive Summary
6. Intratumoral Cancer Therapies Disease Background and Overview
7. Intratumoral Cancer Therapies Treatment and Management
8. Intratumoral Cancer Therapies Epidemiology and Patient Population
9. Intratumoral Cancer Therapies Patient Journey
10. Emerging Intratumoral Cancer Therapies Therapies
11. Intratumoral Cancer Therapies Market Analysis
12. Intratumoral Cancer Therapies KOL Views
13. Intratumoral Cancer Therapies SWOT Analysis
14. Intratumoral Cancer Therapies Unmet Needs
15. Intratumoral Cancer Therapies Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.